Drug | Indication | Phase | Status | Location(s) | Identifier |
---|---|---|---|---|---|
Regdanvimab | COVID-19 infections | II/III | Completed | Multinational | NCT04602000, EudraCT2020-003369-20, CT-P59 3.2 |
Regdanvimab | COVID-19 infections | I | Completed | South Korea, Romania | NCT04593641, EudraCT2020-003165-19, CT-P59 1.2 |
Regdanvimab | COVID-19 infections | I | Completed | South Korea | NCT04525079, EudraCT2020-003065-19, CT-P59 1.1 |